SemiOT: Now on his own, Genaissance founder Ruano has big plans for thinking small
Business New Haven
Gualberto Ruano, founder and until recently CEO of Genaissance Pharmaceuticals, left that Science Park company to start Genomas Inc., which he hopes will develop dynamic, programmable particles smaller than human cells. These particles could recognize and latch onto specific types of cells to monitor cellular activity or deliver medicines. Ruano intends to explore the use of markers to enhance human adaptation and performance. One area Ruano will focus on initially is obesity. "Diet, exercise, nutrition and appetite - all play a role in obesity and all are influenced by our genes," he says. "Only the systems approach of physiogenomics affords the required integration to prevent obesity."
genomas.net
Gualberto Ruano, M.D., Ph.D.
President, GENOMAS
"Physiogenomics and Nanotechnology: A Systems Engineering Approach to Personalized Healthcare"
Gualberto Rua-o, M.D., Ph.D. is President of Genomas, a biotechnology firm specializing in personalized healthcare using genomics, and Director of Cardiovascular Genetics Research at Hartford Hospital. Dr. Ruano is a pioneer in several molecular technologies for profiling genome diversity stemming from population and evolutionary genetics. He has been instrumental in advancing gene haplotypes as the gold standard for pharmacogenetic associations and as one of the fundamental technologies for personalized medicine. He is considered one of the industry's leaders in the impact of gene variation on clinical medicine and drug development. Dr. Ruano is also Adjunct Professor of Biochemistry and Molecular Biology at the George Washington University School of Medicine in Washington, D.C.
bionanotechnology2004.org |
